Why Is Tenax Therapeutics (TENX) Stock Rising Today?

The stock price of Tenax Therapeutics, Inc. (NASDAQ: TENX) has experienced a notable increase, rising by 71.78% to $15.01 a share in mid-day trading. Its patent approval process has advanced significantly, which is responsible for this upsurge.

According to Tenax Therapeutics (TENX), the USPTO has approved its patent application for the use of TNX-103 (oral levosimendan), TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955), and different combinations of levosimendan and cardiovascular drugs. These are meant to improve the way that patients with preserved ejection fraction (PH-HFpEF) and pulmonary hypertension with heart failure do exercises.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Tenax’s intellectual property protection will last until December 2040 if this new patent is approved. The Notice of Allowance from the USPTO indicates an impending grant for expanded IP rights, covering the oral, subcutaneous, and intravenous administration of levosimendan, along with its active metabolites, for treating PH-HFpEF across all therapeutic doses. Furthermore, it encompasses combinations with various cardiovascular drugs for use in PH-HFpEF patients.

This forthcoming patent is poised to augment Tenax’s existing IP claims, encompassing expanded dose ranges and the combination of levosimendan with other drugs for treating PH-HFpEF. Consequently, it bolsters the rationale for future development of drug-drug combinations involving levosimendan. This news complements the recent initiation of investigative sites for Tenax’s Phase 3 LEVEL study, heightening anticipation in the market.

The patents, particularly those concerning the use of IV and oral levosimendan for PH-HFpEF treatment, build upon pivotal findings from the HELP Study conducted by Tenax Therapeutics. Notably, patients treated with levosimendan in the study experienced a statistically significant improvement in the 6-minute walk distance compared to those on placebo. Moreover, patients transitioning from the weekly IV formulation to the oral daily formulation demonstrated further enhancements in their 6-minute walk results.

Tenax Therapeutics’ patent advancements underscore its commitment to developing innovative solutions for PH-HFpEF patients, driving both investor optimism and potential for significant medical advancements in the field.

Most Popular